We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+36.21%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.28B
AUM Growth
+$134M
Cap. Flow
-$102M
Cap. Flow %
-7.96%
Top 10 Hldgs %
51.02%
Holding
98
New
23
Increased
17
Reduced
22
Closed
15

Top Buys

1
ALR
Alere Inc
ALR
+$19.9M
2
NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
+$14.7M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$12M
4
ARCT icon
Arcturus Therapeutics
ARCT
+$9.78M
5
ACGN
Aceragen Inc
ACGN
+$9.6M

Top Sells

1
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$44.6M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$34.2M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$24.4M
4
ASRT
Assertio
ASRT
+$20.7M
5
KND
Kindred Healthcare
KND
+$20.2M

Sector Composition

1 Healthcare 91.84%
2 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLRX
51
BioLineRX
BLRX
$12.6M
$6.54M 0.51%
+5,167
New +$6.36M
ARAY icon
52
Accuray
ARAY
$30.8M
$6.51M 0.51%
700,000
– –
PLXP
53
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$6.48M 0.5%
59,375
– –
TENX icon
54
Tenax Therapeutics
TENX
$420M
$6.42M 0.5%
62
– –
VXRT
55
DELISTED
Vaxart
VXRT
$6.01M 0.47%
237,428
– –
CASC
56
DELISTED
Cascadian Therapeutics, Inc.
CASC
$5.71M 0.44%
583,333
+250,000
+75% +$2.45M
CRDC
57
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$5.59M 0.44%
887,499
– –
XOMA
58
DELISTED
Xoma
XOMA
$5.46M 0.43%
+75,000
New +$5.51M
IRMD icon
59
iRadimed
IRMD
$1.24B
$5.44M 0.42%
357,364
-3,520
-1% -$52K
PGNX
60
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$5.38M 0.42%
900,000
+700,000
+350% +$4.41M
NVDQ
61
DELISTED
Novadaq Technologies Inc.
NVDQ
$5.26M 0.41%
323,863
+12,460
+4% +$185K
CNMD icon
62
CONMED
CNMD
$1.3B
$4.93M 0.38%
97,657
-152,343
-61% -$7.47M
ZSAN
63
DELISTED
Zosano Pharma Corporation
ZSAN
$4.9M 0.38%
+693
New +$5.2M
CAPR icon
64
Capricor Therapeutics
CAPR
$1.13B
$4.87M 0.38%
+70,588
New +$6.09M
SPPI
65
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$4.86M 0.38%
+800,000
New +$5.32M
UNIS
66
DELISTED
Unilife Corporation
UNIS
$4.61M 0.36%
+115,000
New +$4.6M
NBSE
67
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$4.51M 0.35%
+4,438
New +$14.7M
QLTI
68
DELISTED
QLT Inc
QLTI
$4.48M 0.35%
1,145,527
– –
NGNE icon
69
Neurogene
NGNE
$744M
$4.37M 0.34%
26,588
– –
CASM
70
DELISTED
CAS Medical Systems, Inc.
CASM
$3.5M 0.27%
2,618,296
+700,000
+36% +$1.01M
TRNX
71
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$2.62M 0.2%
+100,000
New +$2.53M
APYX icon
72
Apyx Medical
APYX
$180M
$2.42M 0.19%
+1,011,000
New +$3.36M
AMRN
73
Amarin Corp
AMRN
$292M
$2.32M 0.18%
49,594
-62,093
-56% -$1.9M
GHDX
74
DELISTED
Genomic Health, Inc.
GHDX
$2.29M 0.18%
+75,000
New +$2.38M
TEAR
75
DELISTED
TearLab Corporation
TEAR
$1.82M 0.14%
+91,450
New +$2.2M
1 2
3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2015 Portfolio in Review

As of Q1 2015, Broadfin Capital held 98 positions worth $1.28B, up 12% from $1.15B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Broadfin Capital withdrew a net $102M in Q1 2015, closing 15 positions and reducing 22 holdings. Its most notable exit was VOLCANO CORPORATION COM STK, an estimated $44.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 83% a quarter earlier, followed by Consumer Discretionary.

Against the trend, Broadfin Capital opened a new position in Alere Inc worth $22.1M.

  • Broadfin Capital's largest Q1 2015 buy was Alere Inc: 452,423 shares worth $22.1M.
  • Broadfin Capital added most to Aceragen Inc in Q1 2015, an estimated $9.6M increase.
  • Broadfin Capital's biggest Q1 2015 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $34.2M.
  • Broadfin Capital fully exited VOLCANO CORPORATION COM STK in Q1 2015, selling an estimated $44.6M.
  • Broadfin Capital's ten largest holdings make up 51% of its $1.28B portfolio in Q1 2015.
  • Broadfin Capital opened 23 new positions and closed 15 in Q1 2015.
  • Broadfin Capital's portfolio value rose 12% quarter-over-quarter to $1.28B.

Based on Broadfin Capital's 13F filing for Q1 2015, filed 15 May 2015.